Sign Out
Pharmacology: Pharmacodynamics: Etoricoxib is a member of a class of Non-Steroid Anti-Inflammatory Drugs which is highly selective cyclo-oxygenase-2 (COX-2) inhibitor with anti-inflammatory and analgesic properties.
Pharmacokinetics: Absorption: Etoricoxib is well absorbed from the gastrointestinal tract after oral doses. Peak plasma concentrations are reached in about 1 hour in fasted adults.
Distribution: Etoricoxib is approximately 92% bound to plasma protein. At steady state the half-life of etoricoxib is about 22 hours.
Metabolism: The major route of metabolism is via cytochrome P450 isoenzymes including CYP3A4 to from the 6'-hydroxymethyl derivative of etoricoxib, which is then oxidized to the 6'-carboxylic acid derivative, the major metabolite. Both are inactive or only weak cyclo-oxygenase-2 (COX-2) inhibitors.
Excretion: Etoricoxib is excretion mainly via the urine 70% with only 20% of a dose appearing in the faeces.
